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license (http://creativeover 3 decades and to investigate secular trends of dementia.
Methods: Four cohorts covering a period from 1988 to 2013 were used: the Personnes Agees Quid
and Three-City-Bordeaux studies, and the Cognitive Function and Aging Study (CFAS) I and II.
Mini–Mental State Examination scores at clinical diagnosis were evaluated over a 24-year
follow-up period in French studies. An algorithmic approach was applied to CFAS I and II to provide
dementia prevalence and incidence estimates.
Results: A significant increase of the Mini–Mental State Examination score at diagnosis was
observed until 2000 and a significant decrease after. We reported a prevalence of 8.8% for CFAS I
(1990–1993) compared with a prevalence of 6.5% in CFAS II (2008–2011). The 2-year incidence
rate was estimated at 31.2/1000 (95% confidence interval 5 28.0–34.8) for CFAS I and 15.0/1000
(95% confidence interval 5 13.5–16.7) for CFAS II.
Discussion: Applying a stable algorithm to different cohorts across time can provide a robust method
for time trends estimation.
 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Dementia; Secular trends; Diagnosis; Incidence; Prevalence1. Introduction
Dementia is a syndrome consisting of deterioration in
cognitive functions sufficient to impair a person’s daily life
and activities. To describe the extent of dementia as a public
health priority, many population-based studies following
older people over time have been undertaken during the
past 30 years [1,2]. Research on the descriptive
epidemiology of dementia has identified several challenges
in the field: standardization of diagnostic approaches fordeclared that no conflict of interest exists.
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he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).dementia subtype and mild forms of cognitive decline;
dealing with participant selection and attrition, differential
mortality, and incidence for prevalence estimations;
dementia at the end of life and terminal decline;
substantial underdiagnosis by the health care system [3].
Diagnosis of the dementia syndrome is sensitive to such
challenges [4,5]. Recently researchers have evaluated
changes in dementia prevalence and incidence over time
[6–14]. However, to provide accurate estimations,
consistent dementia diagnosis across studies and time is
required. The relationship of both clinical and consensus
diagnosis of dementia can be examined across time, and
also in relation to other types of measurement. The
diagnosis of dementia, a clinical syndrome, is based on aimer’s Association. This is an open access article under the CC BY-NC-ND
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Statistical Manual of Mental Disorders (DSM) [15]. These
diagnostic criteria do not have clear thresholds or specific
measures to define the level of cognitive decline and its con-
sequences, leaving the ultimate decision to clinical judgment
or consensus diagnosis. Although diagnostic criteria have
not fundamentally changed, there have been substantial so-
cietal and clinical shifts in dementia awareness, likely to
have resulted in interclinician and intraclinician variability.
Recently, a few studies on the evolution of dementia over
time have hypothesized that the diagnosis of dementia is
likely to have evolved over 20 years and that algorithmic
diagnosis could be more stable [16–18]. Changes in
prevalence and incidence of any disorder, including
dementia, are known to be influenced when diagnostic
processes change over time, resulting in systematically
different estimations (e.g., diabetes mellitus, hypertension)
[19]. The studies presented in this work have determined de-
mentia cases using two different algorithms in place of or in
addition to clinical diagnosis: the Automated Geriatric Ex-
amination for Computer-Assisted Taxonomy (AGECAT) al-
gorithm, a well-known and validated automated computer
algorithm used in the British cohorts in the Cognitive Func-
tion and Aging Study (CFAS) I and CFAS II [20,21] and a
“Comparative Dementia Algorithm (CDA)” developed
from French cohorts [17]. Clinical diagnoses in French co-
horts showed no change in dementia incidence over 2 de-
cades, whereas the algorithmic diagnosis revealed a
decrease, supporting the evolution hypothesis and high-
lighting the importance of using a stable diagnosis of demen-
tia.
This study aimed (1) to examine the evolution of clinical
dementia diagnosis over 3 decades, by analyzing the cogni-
tive performance of people given a study diagnosis of inci-
dent dementia. A comparison of these with the cases
diagnosed by a CDA method on French data was also con-
ducted to establish the nature of change, if any; (2) as a vali-
dation of this algorithm, an adaptation was also applied to
the British data to perform prevalence and incidence anal-
ysis, to provide a comparison with the validated AGECAT
algorithm.2. Methods
2.1. Study populations
Participants, aged 65 years and older, from four different
population-based cohorts from France (Personnes Agees
Quid [PAQUID] and Three-City) and UK (CFAS I and II)
have been used in this study (cf. Supplementary Fig. 1).
The PAQUID cohort was formed in 1988–1989 with a
representative sample of 3777 participants living at home
in the departments of Gironde and Dordogne. The selection
was stratified by sex, age, and size of urban unit. Respon-
dents have been followed up for 27 years. The Three-City
(3C-Bordeaux) cohort, starting in 1999, recruited 2104participants from the Urban Community of Bordeaux,
within 10 districts. Participants have been followed up for
14 years. For these two French cohorts, standardized ques-
tionnaires assessing sociodemographic, medical, cognitive,
and functional data were administered by trained neuropsy-
chologists during face-to-face interviews, at baseline and at
each follow-up. Participants were followed-up every 2 to 3
years even after institutionalization. At each follow-up, vital
status was systematically recorded for all the participants.
TheMedical Research Council CFAS I: between 1989 and
1994, baseline interviews were conducted in six geographical
areas in England and Wales, and subjects were followed up
for 10 years. A two stage process, with screening followed
by diagnostic assessment, was used in CFAS I, weighted
across the cognitive performance as Mini–Mental State Ex-
amination (MMSE) and AGECAT original items in screen.
Data from three of the English areas of Medical Research
Council CFAS—Cambridgeshire, Newcastle, and Notting-
ham [22], where interviews were carried out between
December 1990 and July 1993—were selected for analyses,
providing 7635 subjects, from which a subpopulation of
1459 individuals underwent assessment. Between November,
2008, and October, 2011, new fieldwork in the same
geographical areas was carried out to provide CFAS II esti-
mates on 7762 subjects, which could be directly compared
with CFAS I. CFAS I and CFAS II had identical sampling ap-
proaches, methods, and diagnostic approach apart from the
simplification of design from two stage to one stage at base-
line and incidence phase through combination of screening
and assessment interviews. Full details of the studies have
been described elsewhere [16,22–24].2.2. Diagnostic methods
In the French cohorts, a clinical diagnosis was available,
whereas in the British cohorts, the AGECAT algorithm was
applied. Moreover, in the four studies, a CDAwas applied.
For both PAQUID and 3C populations, the clinical diag-
nosis was made following a three-step procedure. The first
step was a cognitive evaluation made by the neuropsycholo-
gist through a series of psychometric tests. Participants who
had a high likelihood of dementia, based on their neuropsy-
chological performances or decline relative to a previous ex-
amination, were then examined by a senior neurologist. The
diagnosis of dementia was based on the DSM-III-R or the
DSM-IV criteria. In case of refusal or death between the first
and second steps, additional information was gathered from
the informant and the medical practitioner. Then, each case
was discussed by a validation committee composed of neu-
rologists and geriatricians and directed by J.F.D. to provide a
final diagnosis.
In CFAS I and II, the AGECATalgorithm used was based
on the Geriatric Mental State Examination that provides
relevant information to determine dementia syndrome in
older population [20,25]. Missing data within an interview
could prevent the algorithmic diagnosis, and for
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for CFAS II as for CFAS I, which was a review of all
available information by diagnostician (C.B.), applying
DSM-IIIR criteria. Many of these individuals with missing
data had severe cognitive impairment and were not able to
respond to the interview questions. The Geriatric Mental
State–AGECAT has been validated against internationally
accepted earlier diagnostic criteria (DSM-IIIR) [21].
The CDA approach was a cognition-disability algorithm.
For the French data, we used a previously published algorithm
[17]. This diagnosis was based on cognitive and functional as-
sessments using MMSE and four Instrumental Activities of
Daily Living (4IADL) associated with cognition (ability to
use the telephone, transportation, responsibility for medica-
tions, and ability to manage its budget) to fit dementia defini-
tion. The algorithmic diagnosis was then defined by an
MMSE score of ,24 (or a missing MMSE score for “cogni-
tive reason” such as major aphasia, mutism, comprehension
problem) AND a 4IADL score of .1 (disability, even mild,
for more than one activity out of the 4). For the English
data, information on disability was not recorded in the same
way as in France, so the algorithm has been adapted for
comparative purposes. It was based on the MMSE score
and on disability on IADLs and ADLs (ability to wash all
over or bath, to prepare and cook a hot meal, and to put on
shoes and socks or stockings). The algorithm was defined
by an MMSE score of ,24 AND if the respondent need
more than partial help with at least one of the three abilities.2.3. Statistical analyses
Sociodemographic characteristics, MMSE, and disability
score at baseline have been compared between populations.
To explore evolution of the clinical diagnosis over time,
cognitive status at diagnosis using the MMSE score was
described. The scores of incident clinical cases at each
follow-up of the whole PAQUID and 3C-Bordeaux studies
were described using mean scores according to study and
educational level. Prevalent cases at inclusion were removed,
and only incident cases at each follow-up were kept. Linear
splines regression of MMSE scores according to time, age at
diagnosis, gender, study, and educational level were also per-
formed.
The cases diagnosed during the first 10 years of follow-up
from PAQUID and 3C-Bordeaux were then classified ac-
cording to the concordance or divergence of clinical and
algorithmic diagnosis. A comparison of the characteristics
of discordant cases was analyzed with sociodemographic,
cognitive, and functional factors according to two cate-
gories: dementia in clinical diagnosis but no dementia in
the algorithmic approach, and no dementia in clinical diag-
nosis but dementia in the algorithmic approach.
Finally, to validate the CDA, prevalence and incidence in
both CFAS I and II have been estimated and discussed in
relation to previously published prevalence and incidence re-
sults obtained based on AGECATalgorithm. For CFAS I, theprevalence was provided from the first wave (inclusion) on
all subjects. For CFAS II, prevalence was provided from
the first wave on all subjects. Prevalence has been weighted
and standardized on the age and sex repartition of the 2011
UK population. Two-year incidence has been estimated with
a weighted Poisson regression on all subjects for both CFAS
I and II. An inverse probability weighting has been used
based on both the probability of being included in the study,
taking participation rate difference into account, and the
probability of having a diagnosis, taking attrition into ac-
count. Finally, comparisons of both prevalence and inci-
dence between CFAS I and CFAS II are provided.3. Results
3.1. Population characteristics
Global characteristics of the four cohort populations are
presented in Table 1 (including the CFAS I subpopulation).
The mean age at inclusion was around 75 years with more
women thanmen. PAQUID and CFAS I participants reported
less years of education and had a lowerMMSE score at base-
line than 3C and CFAS II. Flow charts of the four popula-
tions are presented in Supplementary Fig. 1.
3.2. Evolution of the clinical diagnosis
In total, 1318 incident cases where clinically diagnosed in
3C and PAQUID over the follow-up, with 1250 with values al-
lowing for adjustment ofMMSE scores at diagnosis. The crude
means of theMMSE at clinical diagnosis for each follow-up in
PAQUID and 3C-Bordeaux are shown in Fig. 1. The means of
theMMSEat diagnosiswerehigher inhigher-educated subjects
of 3C-Bordeaux than in lower-educated subjects of 3C and in
PAQUID at all follow-up times. Overall, the regression model
showed a significant increase in the MMSE score at diagnosis
before 2001 (b 5 0.30/y, P , .0001) and then a significant
decrease of the MMSE score after 2001 (b 5 20.34/y,
P, .0001), adjusted on age at diagnosis, sex, study, and educa-
tional level. Subjects from 3C had significantly higher levels of
MMSE scores at diagnosis (b5 1.16,P5 .006), aswell as sub-
jectswith higher educational level comparedwith thosewithout
diploma (b5 2.87, P, .0001).
3.3. Characteristics of diagnostic discordance
Cases from the 10-year follow-up of 3777 subjects of PA-
QUID and 2104 subjects of 3C-Bordeaux have been classi-
fied according to both clinical and algorithmic diagnosis
(CDA). On the 5881 subjects, 4801 (81.6%) did not have de-
mentia at either diagnosis and 535 (9.1%) were diagnosed
with dementia by the two diagnosis over the 10-year
follow-up; 389 (6.6%) subjects were algorithmic cases
only, and 156 (2.6%) subjects were clinical cases only.
The characteristics of discordant cases are described in
Table 2. In 3C-Bordeaux, people were more likely to be
diagnosed by clinical diagnosis than algorithm. They were
Table 1
Descriptive data on cohorts
Characteristic PAQUID CFAS I 3C CFAS II
Inclusion date 1988–1989 1990–1993 1999–2000 2008–2011
Number of participants
Total population 3777 7635 2104 7762
Subpopulation* - 1459 - -
Age at baseline: mean (SD)
Total population 75.5 (6.9) 75.8 (7.1) 74.6 (5.1) 75.7 (7.3)
Subpopulation* - 77.4 (7.9) - -
Gender (women): n (%)
Total population 2200 (58.3) 4594 (60.1) 1288 (61.2) 4228 (54.5)
Subpopulation* - 921 (63.6) - -
Low educational levely: n (%)
Total population 2980 (78.9) 5532 (74.1) 872 (41.5) 2045 (26.8)
Subpopulation* - 1065 (79.3) - -
MMSE score at baseline: mean (SD)
Total population 25.6 (3.7) 24.8 (6.1) 27.2 (2.4) 26.8 (3.5)
Subpopulation* - 20.9 (7.4) - -
Abbreviations: PAQUID, Personnes Agees Quid; CFAS, Cognitive Function and Aging Study; MMSE, Mini–Mental State Examination.
*Subjects with assessment by AGECAT algorithm diagnosis.
yLow educational level: less than 10 years of study.
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diagnosed by the algorithm. Age at diagnosis was the
same for both categories, but the MMSE score at diagnosis
was higher for subjects diagnosed by clinical diagnosis
than for the one diagnosed by algorithm only.3.4. CFAS prevalence and incidence estimates: The
cognition-disability algorithm approach. Comparison with
AGECAT estimates3.4.1. Prevalence
In CFAS I total population at baseline, the CDA algorithm
was incomplete for 274 individuals. On the 7365 remaining

















Fig. 1. MMSE (mean) at time of study clinical diagnosis (incident) across time in 3
MMSE, Mini–Mental State Examination.diagnosis of dementia (CDA) (weighted and standardized
percentage 5 8.8%). Previously published results on CFAS
based on the AGECAT algorithm estimated a prevalence of
8.3%. Of the CFAS II total population at baseline, 404 of
the 7762 had incomplete data for the CDA and were not in
the analysis. CDA then classified 367 as having dementia
(weighted and standardized percentage5 5.7%). Previously
published results on CFAS II based on the AGECAT algo-
rithm reported a prevalence of 6.5%.
Based on the CDA, dementia prevalence has declined by
35% between 1990–1993 and 2008–2011.
3.4.2. Incidence
For CFAS I, 4648 of the 6135 respondents without prev-





C-Bordeaux and PAQUID. Abbreviations: PAQUID, Personnes Agees Quid;
Table 2
Characteristics of participants according to clinical or algorithmic
diagnostic method in the first 10 years of follow-up in PAQUID and 3C-








3C/PAQUID, % (n) 60.9 (95) 24.2 (94)
Women, % (n) 60.3 (94) 72.7 (283)
Low education, % (n) 21.1 (33) 57.8 (225)
Diagnosis Rosow disability, % (n) 90.2 (138) 98.2 (376)
Diagnosis Katz disability, % (n) 13.1 (20) 29.7 (114)
Diagnosis age, mean (s.d.) 83.4 (5.5) 83.5 (6.2)
Diagnosis MMSE, mean (s.d.) 23.5 (3.0) 19.9 (4.0)
Abbreviations: PAQUID, Personnes Agees Quid; CFAS, Cognitive Func-
tion and Aging Study; MMSE, Mini–Mental State Examination.
*Diagnosis type 5 0: no dementia and 1: dementia.
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dementia (based on the CDA definition) during the 2 years.
For CFAS II, 4964 of 6574 without prevalent dementia
defined by CDA were re-interviewed at 2 years, of whom
137 (2.7%) individuals fulfilled the CDA. The 2-year age
and sex adjusted incidence rates were thus 31.2/1000 (95%
confidence interval [CI] 5 28.0–34.8) for CFAS I and
15.0/1000 (95% CI 5 13.5–16.7) for CFAS II. Previously
published results on CFAS based on the AGECATalgorithm
have found an incidence of 20.0/1000 (95% CI5 16.9–23.8)
for CFAS I and 17.7/1000 (95% CI 5 15.2–20.9) for CFAS
II. Incidence rates and confidence intervals per age and sex
based on the CDA definition have been provided for both
CFAS I and II in Table 3. CFAS II incidence estimates
were lower than CFAS I, for both men and women and
each age category, and women always had a higher inci-
dence rate than men, although somewhat reduced in CFAS
II compared with CFAS I.Table 3
Incidence rates in CFAS I and CFAS II by age and gender, defined using
CDA and weighted for nonresponse and population selection
/1000 PY
CFAS I CFAS II
Rate 95% CI Rate 95% CI
Men
65–69 8.5 6.6–11.0 4.1 3.2–5.3
70–74 11.4 9.0–14.4 5.5 4.3–6.9
75–79 19.5 15.8–24.0 9.4 7.6–11.5
80–84 53.0 44.4–63.4 25.5 21.5–30.2
851 106.9 88.7–128.7 51.3 43.4–60.8
Women
65–69 12.8 10.1–16.2 6.1 4.8–7.8
70–74 17.1 13.7–21.3 8.2 6.6–10.3
75–79 29.3 24.4–35.3 14.1 11.6–17.1
80–84 79.7 68.9–92.2 38.3 33.0–44.4
851 160.7 139.0–185.7 77.2 67.5–88.3
Abbreviations: CFAS, Cognitive Function and Aging Study; CDA,
Comparative Dementia Algorithm.4. Discussion
This article has described the evolution over 25 years of
the cognitive status of incident cases of dementia when
they were diagnosed based on clinical diagnosis. Compared
with cases solely diagnosed by CDA, those with a clinical
diagnosis only were more highly educated and diagnosed
with a higher MMSE score. Prevalence and incidence esti-
mates were a little higher using the CDA approach compared
with the AGECATalgorithm in CFAS I and similar in CFAS
II.
An important strength of this study was the use of four
well-recognized cohort studies, with longitudinal follow-
up covering a 25-year period and with a high number of sub-
jects. Moreover, results are based on three different diag-
nostic approaches already published, one clinical and two
algorithmic. Among the different algorithms used, gold stan-
dards will depend on purpose and motivation for diagnosis
and whether research or clinical settings. However, the
CDA approach has the advantage of being simple and easy
to use in a large number of studies. It needs to be stated
that the diagnostic approach must be appropriate for the pur-
pose [26]. When studying secular trends of dementia, stabil-
ity of the diagnosis over time is the main requirement. A
limitation is that our results on possible evolution or bound-
ary creep of dementia diagnosis are only based on the two
French studies with a clinical diagnosis available. Further
replication on other population studies is necessary to
confirm our results. Another issue is a limit of our CDA defi-
nition that does not allow disentangling the part of functional
and/or cognitive deficits attributable to comorbidities unre-
lated to dementia. For example, disabilities due to comorbid-
ities such as blindness, Parkinson’s disease, or stroke are
similarly accounted for by the algorithm as disabilities due
to repercussion of cognitive impairment. This could explain
part of the difference between cases diagnosed by clinic and
by algorithm only (6.6% CDA1/clin2).
The analysis of MMSE scores at clinical diagnosis from
the beginning of the 90s to the beginning of 2010 demon-
strates an evolution of cognitive status of participants at
time of dementia diagnosis across time and study in France.
Between 1992 and 2001 in PAQUID, we found that subjects
were increasingly diagnosed earlier—at a less severe
stage—over time. The improvement of disease knowledge
and the introduction of treatments may have led to diagnosis
at earlier stage. A German study based on memory clinics
also found a trend to earlier diagnosis between 1985 and
2009 [27]. After 2001 however in the French studies, we
found that incident cases were progressively diagnosed
when more severely cognitively impaired over time. This
decrease may be the result of the aging of the whole cohorts,
although regression models have been adjusted on age at
diagnosis. Failure to find new efficient treatments and public
perception of the impact of diagnosis on patients could also
be possible explanations for this change. The diagnosis of
dementia was made earlier in 3C than in PAQUID. The
L. Grasset et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 10 (2018) 490-497 495higher educational level of the 3C participants partly ex-
plains this difference. It may also be explained by the intro-
duction of the Free and Cued Selective Reminding Test in
the 3C questionnaires [28]. This provides a finer/more subtle
indication of episodic memory impairments of the partici-
pants and may have led to the differences with the PAQUID
study. Only later follow-up, with validation through knowl-
edge of progression, can the comparison of relative perfor-
mance be known and it may be that overdiagnosis is
occurring.
The instability of the clinical diagnosis led to the emer-
gence of the algorithmic approach to diagnose dementia in
cohort studies. The comparison of dementia incidence 10
years apart in PAQUID and 3C has shown that the type of
diagnosis used can lead to mixed results and have an influ-
ence on conclusions about secular trends [17]. Only the algo-
rithmic diagnosis showed a decrease in the incidence of
dementia with the trends stable for clinical diagnosis.
Similar observations have been made in the comparison of
dementia prevalence 20 years apart in the PAQUID and
Agrica-MSA-IFR de Sante Publique, Aging Multidisci-
plinary Investigation studies [29]. In the Framingham study,
the authors have reviewed a second time each case diag-
nosed before 2001 to apply up-to-date criteria [8]; however,
the same indicators are needed to control for evolution. In
the Health and Retirement Study, an algorithmic approach
based on cognitive deficit assessed with a 27-point scale
has also been used [14,30]. These results provide further
evidence to support the use of approaches that are less
prone to secular changes in diagnostic thresholds when
evaluating time trends and computing projections. When
comparing cases diagnosed by either the clinical or the
CDA diagnosis in the two French populations, it appeared
that cases diagnosed by purely clinical diagnosis were
more educated and had a higher MMSE score at diagnosis
than the cases diagnosed by the algorithm only, thus
diagnosing people earlier in the disease course than the
algorithm (or indeed overdiagnosis). The CDA items and
cut points were mapped to the dementia syndrome criteria.
In 2015, the major change between the DSM-IVand the lat-
est edition, the DSM-V, heralded the “end” of the word de-
mentia within the diagnostic criteria, with substitution of
“major neurocognitive disorder,” where the loss of indepen-
dent functioning remains an important criterion. Algorithms
have become even more relevant as these are highly compat-
ible with this approach.
The AGECAT algorithm was validated according to the
DSM-III-R criteria, and prevalence and incidence estimates
and time trends have already been published for CFAS I and
II [16,18]. One difficulty in CFAS I was the two-phase
design where a majority of individuals had not undergone
the assessment process, although sampling and assessment
was across the cognitive spectrum. The estimations show
that the CFAS CDA prevalence is slightly higher for CFAS
I, and for CFAS II lower when compared with the prevalence
estimated using AGECAT diagnosis, from a full likelihoodmodel for study design, missing data, and inverse probability
weighting for initial nonresponse. For CFAS I, the incidence
estimates using the CDA were much higher than the inci-
dence rates found with the AGECAT and Bayesian proced-
ure but slightly lower for CFAS II. Using the CDA
approach thus showed an even more marked reduction in
incidence of dementia between CFAS I and II than has
been published. The results also showed a significant decline
in women, not found with the AGECAT. This could be ex-
plained by the fact that disability in women has improved be-
tween the two generations and these measures of disability
were not directly part of the AGECAT algorithm unlike the
CDA algorithm [31].
To conclude, secular trends analyses of dementia are
important and have attracted considerable attention. Investi-
gating the best ways to provide the most accurate estima-
tions is critical when such estimations are used to predict
future dementia numbers, and hence facilitate policy and
care planning, worldwide. It is therefore essential to employ
a stable diagnosis over time and studies. We provide here a
simple and easy to use algorithmic approach that can be
applied to most pre-existing cohorts. Further studies
exploring secular trends of dementia in multiple cohorts
could stabilize/standardize their methods over time by using
this approach.Acknowledgments
Declaration of interests: L.G., F.E.M., K.P., A.F.-S., C.H.,
and C.B. report no disclosure. J.F.D. received research grants
from IPSEN and Roche, outside the submitted work.
The PAQUID study was funded by IPSEN France, NOVAR-
TIS Pharma France, and the CNSA (Caisse Nationale de
Solidarite et d’Autonomie). The Three-City study is con-
ducted under a partnership agreement between the Institut
National de la Sante et de la Recherche Medicale (IN-
SERM), the University Bordeaux 2 Victor Segalen and
Sanofi-Aventis. The Fondation pour la Recherche Medicale
funded the preparation and initiation of the study. The Three-
City study is also supported by the Caisse Nationale
d’Assurance Maladie des Travailleurs Salaries, Direction
Generale de la Sante, MGEN, Institut de la Longevite, Con-
seils Regionaux d’Aquitaine et Bourgogne, Fondation de
France, Ministry of Research-INSERM Program “Cohortes
et collections de donnees biologiques”, Agence Nationale
de la Recherche ANR PNRA 2006 and LongVie 2007, the
“Fondation Plan Alzheimer” (FCS 2009-2012), and the
CNSA (Caisse Nationale de Solidarite et d’Autonomie).
CFAS thanks participants, their families, general practi-
tioners, and primary care trusts in Cambridgeshire, Newcas-
tle, and Nottingham for their cooperation and support. CFAS
I was funded by MRC Grant No: G9901400; CFAS II was
funded by MRC Grant No: G0602033 and the Alzheimer’s
Society UK award No: 294. The funders had no role in study
design, in data collection, analysis, and interpretation, or in
writing of report. The corresponding author had full access
L. Grasset et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 10 (2018) 490-497496to all the data in the study and had final responsibility for the
decision to submit for publication.
Supplementary data
Supplementary data related to this article can be found at
https://doi.org/10.1016/j.dadm.2018.07.005RESEARCH IN CONTEXT
1. Systematic review: We reviewed the literature using
traditional (e.g., PubMed) sources. While secular
trends of dementia prevalence and incidence have
been reported in several recent publications, there
have been only few studies investigated evolution
of clinical diagnosis of dementia. These relevant ci-
tations are appropriately cited.
2. Interpretation: This work shows a significant evolu-
tion of the clinical diagnosis of dementia between
time and studies, with dementia being progressively
diagnosed earlier before 2000 and with a trend to-
ward more advanced cognitive impairment after
2000. It also confirms the evidence of a decrease in
the prevalence and incidence of dementia over the
last decades, using an algorithmic diagnostic
approach.
3. Future directions: This finding highlights the impor-
tance to apply stable diagnosis over time and studies
when studying secular trends of dementia. Further in-
vestigations regarding potential reasons for the
declining trends of dementia are required.References
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